When the panel was treated with venetoclax, only p185+ B-ALL cells re-programmed with human BCL-2 (IC50 = 12 nM) responded by inducing apoptosis, while cells expressing other anti-apoptotic molecules were resistant to ABT-199-mediated killing (IC50 > 5 μM) (Figure 3B). The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.